StockData
NovoCure Ltd logo

NovoCure Ltd (NVCR) stock

NVCRNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 9/3033% below fair value
$10.73−0.41 (-3.68%)

Close on Nov 18, 2026Market cap $1.25BP/E –Yield –

NovoCure net income

Net income is the profit left for shareholders after every expense, interest and tax.

NovoCure's net income for the twelve months ending Sep 30, 2026 was -$121.73M. For fiscal 2025 it was -$136.23M. The highest annual figure on record is $19.81M in fiscal 2020.

Annual net income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$136.23M–
FY2024Dec 31, 2024-$168.63M–
FY2023Dec 31, 2023-$207.04M–
FY2022Dec 31, 2022-$92.53M–
FY2021Dec 31, 2021-$58.35M-394.6%
FY2020Dec 31, 2020$19.81M–
FY2019Dec 31, 2019-$7.23M–
FY2018Dec 31, 2018-$63.56M–
FY2017Dec 31, 2017-$61.66M–
FY2016Dec 31, 2016-$131.85M–
FY2015Dec 31, 2015-$111.58M–
FY2014Dec 31, 2014-$80.68M–
FY2013Dec 31, 2013-$77.37M–

Quarterly net income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026-$10.44M–
Q2 FY2026Jun 30, 2026-$15.66M–
Q1 FY2026Mar 31, 2026-$71.14M–
Q4 FY2025Dec 31, 2025-$24.50M–
Q3 FY2025Sep 30, 2025-$37.27M–
Q2 FY2025Jun 30, 2025-$40.14M–
Q1 FY2025Mar 31, 2025-$34.32M–
Q4 FY2024Dec 31, 2024-$65.92M–
Q3 FY2024Sep 30, 2024-$30.57M–
Q2 FY2024Jun 30, 2024-$33.38M–
Q1 FY2024Mar 31, 2024-$38.76M–
Q4 FY2023Dec 31, 2023-$47.08M–
Q3 FY2023Sep 30, 2023-$49.49M–
Q2 FY2023Jun 30, 2023-$57.42M–
Q1 FY2023Mar 31, 2023-$53.06M–
Q4 FY2022Dec 31, 2022-$37.30M–
Q3 FY2022Sep 30, 2022-$26.58M–
Q2 FY2022Jun 30, 2022-$24.01M–
Q1 FY2022Mar 31, 2022-$4.65M–
Q4 FY2021Dec 31, 2021-$26.46M-638.1%
Q3 FY2021Sep 30, 2021-$13.12M-241.4%
Q2 FY2021Jun 30, 2021-$14.64M-984.7%
Q1 FY2021Mar 31, 2021-$4.13M-204.5%
Q4 FY2020Dec 31, 2020$4.92M+15.4%
Q3 FY2020Sep 30, 2020$9.28M+381.0%
Q2 FY2020Jun 30, 2020$1.66M–
Q1 FY2020Mar 31, 2020$3.95M–
Q4 FY2019Dec 31, 2019$4.26M–
Q3 FY2019Sep 30, 2019$1.93M–
Q2 FY2019Jun 30, 2019-$1.27M–
Q1 FY2019Mar 31, 2019-$12.15M–
Q4 FY2018Dec 31, 2018-$15.63M–
Q3 FY2018Sep 30, 2018-$11.69M–
Q2 FY2018Jun 30, 2018-$15.51M–
Q1 FY2018Mar 31, 2018-$20.72M–
Q4 FY2017Dec 31, 2017-$10.95M–
Q3 FY2017Sep 30, 2017-$11.50M–
Q2 FY2017Jun 30, 2017-$21.17M–
Q1 FY2017Mar 31, 2017-$18.05M–
Q4 FY2016Dec 31, 2016-$22.17M–

More NovoCure figures

See a number that looks wrong?